InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Telomir Pharmaceuticals, Inc.

TELO Clue Score37
United States Fiscal year ends December CIK 0001971532
$1.12 -2.61% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $1.12 −41.97% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 9 Feb 2024. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
Net income
Fiscal year 2022Net income−0.9EPS, diluted−0.03Fiscal year 2023Net income−13.1EPS, diluted0.48Fiscal year 2024Net income−16.5EPS, diluted−0.56 −216.7%Fiscal year 2025Net income−10.4EPS, diluted−0.33
FY2022FY2023FY2024FY2025
Net income −0.9 −13.1 −16.5 −10.4
Growth
EPS, diluted −0.03 0.48 −0.56 −0.33
Growth −216.7%

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flow
Fiscal year 2022Operating cash flow−0.5Fiscal year 2023Operating cash flow−3.9Fiscal year 2024Operating cash flow−5.1Fiscal year 2025Operating cash flow−3.7
FY2022FY2023FY2024FY2025
Operating cash flow −0.5 −3.9 −5.1 −3.7

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2022Shareholders’ equity−0.9Fiscal year 2023Shareholders’ equity3.4Fiscal year 2024Cash1.3Shareholders’ equity0.6Fiscal year 2025Shareholders’ equity5.9
FY2022FY2023FY2024FY2025
Cash n/a n/a 1.3 n/a
Shareholders’ equity −0.9 3.4 0.6 5.9

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2022 31 Dec 2022 FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Revenue and profit
0.8 1.6 2.2 2.4
0.0 0.6 9.6 8.1
−0.9 −13.1 −16.5 −10.4
Growth
Per share
−0.03 0.48 −0.56 −0.33
−0.03 0.48 −0.56 −0.33
Growth −216.7%
26.8 27.3 29.5 31.7
26.8 27.3 29.5 31.7
Growth +1.8% +8.2% +7.2%

Five years in brief

Worked out from the figures above, not from a press release
  • A net loss in 4 of 4 years on file.